{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:05:29Z","timestamp":1794549929680,"version":"4.9.1"},"reference-count":99,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Acute myeloid leukemia (AML) is the main indication for allogeneic hematopoietic cell transplantation, but relapse is common because of chemotherapy resistance and immune escape. We discuss the mechanisms of AML immune evasion including loss or downregulation of MHC class I and II, reduced tumor necrosis factor\u2013related apoptosis-inducing ligand (TRAIL) receptor expression, inhibitory metabolite production, inhibitory ligand expression, impaired proinflammatory cytokine production, and AML niche alterations. Understanding and targeting these mechanisms could enhance outcomes for patients with AML undergoing allogeneic hematopoietic cell transplantation and immunotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We discuss the mechanisms of AML immune evasion including loss or downregulation of MHC class I and II, reduced TRAIL receptor expression, inhibitory metabolite production, inhibitory ligand expression, impaired proinflammatory cytokine production, and AML niche alterations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0063","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T15:03:36Z","timestamp":1743519816000},"page":"168-181","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune Escape of Acute Myeloid Leukemia after Transplantation"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-7342","authenticated-orcid":false,"given":"Nguyen Huong Jenny Giang","family":"Ho","sequence":"first","affiliation":[{"name":"1Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-6351","authenticated-orcid":false,"given":"Nana","family":"Talvard-Balland","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7502-0431","authenticated-orcid":false,"given":"Natalie","family":"K\u00f6hler","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg, Germany."},{"name":"2CIBSS \u2013 Centre for Integrative Biological Signaling Studies, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"2026041309331539500_bib1","doi-asserted-by":"crossref","first-page":"917.e1","DOI":"10.1016\/j.jtct.2024.06.021","article-title":"Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry","volume":"30","author":"Cusatis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026041309331539500_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.coi.2005.01.010","article-title":"Immunotherapy of cancer through targeting of minor histocompatibility antigens","volume":"17","author":"Hambach","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"2026041309331539500_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"2026041309331539500_bib4","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1158\/0008-5472.CAN-11-0108","article-title":"PD-1\/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation","volume":"71","author":"Norde","year":"2011","journal-title":"Cancer Res"},{"key":"2026041309331539500_bib5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbmt.2017.11.027","article-title":"Increased coexpression of PD-1, TIGIT, and KLRG-1 on tumor-reactive CD8+ T cells during relapse after allogeneic stem cell transplantation","volume":"24","author":"Hutten","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041309331539500_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"2026041309331539500_bib7","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol"},{"key":"2026041309331539500_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-021-00453-z","article-title":"Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study","volume":"11","author":"Reville","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026041309331539500_bib9","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2019-127345","article-title":"Multi-center phase 2 study of pembroluzimab (pembro) and azacitidine (AZA) in patients with relapsed\/refractory acute myeloid leukemia (AML) and in newly diagnosed (\u226565 Years) AML patients","volume":"134","author":"Gojo","year":"2019","journal-title":"Blood"},{"key":"2026041309331539500_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026041309331539500_bib11","doi-asserted-by":"crossref","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia: a meta-analysis","volume":"12","author":"G\u00f3mez-Llobell","year":"2022","journal-title":"Front Oncol"},{"key":"2026041309331539500_bib12","doi-asserted-by":"crossref","first-page":"634435","DOI":"10.3389\/fimmu.2021.634435","article-title":"The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation","volume":"12","author":"K\u00f6hler","year":"2021","journal-title":"Front Immunol"},{"key":"2026041309331539500_bib13","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"2026041309331539500_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"2026041309331539500_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041309331539500_bib16","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.2022017686","article-title":"Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-na\u00efve settings","volume":"141","author":"Garcia","year":"2023","journal-title":"Blood"},{"key":"2026041309331539500_bib17","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"key":"2026041309331539500_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bjh.19007","article-title":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation\u2014immune signature correlates with response","volume":"203","author":"Apostolova","year":"2023","journal-title":"Br J Haematol"},{"key":"2026041309331539500_bib19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"2026041309331539500_bib20","doi-asserted-by":"crossref","first-page":"810284","DOI":"10.3389\/fimmu.2022.810284","article-title":"Case report: preemptive treatment with low-dose PD-1 blockade and azacitidine for molecular relapsed acute myeloid leukemia with RUNX1-RUNX1T1 after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"2026041309331539500_bib21","doi-asserted-by":"crossref","first-page":"e000778","DOI":"10.1136\/jitc-2020-000778","article-title":"M1(hot) tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer","volume":"8","author":"Garrido-Martin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026041309331539500_bib22","doi-asserted-by":"crossref","first-page":"692800","DOI":"10.3389\/fcell.2021.692800","article-title":"Macrophages in acute myeloid leukaemia: significant players in therapy resistance and patient outcomes","volume":"9","author":"Miari","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026041309331539500_bib23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2016.143180","article-title":"Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner","volume":"101","author":"Al-Matary","year":"2016","journal-title":"Haematologica"},{"key":"2026041309331539500_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"2026041309331539500_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","article-title":"Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy","volume":"7","author":"Dama","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026041309331539500_bib26","doi-asserted-by":"crossref","first-page":"e177460","DOI":"10.1172\/JCI177460","article-title":"Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice","volume":"134","author":"Talvard-Balland","year":"2024","journal-title":"J Clin Invest"},{"key":"2026041309331539500_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2023-180876","article-title":"TIM-3 inhibitor sabatolimab for patients with acute myeloid leukemia (AML) with measurable residual disease (MRD) detected after allogeneic stem cell transplantation (AlloSCT): preliminary findings from the phase Ib\/II stimulus-AML2 study","volume":"142","author":"Zeiser","year":"2023","journal-title":"Blood"},{"key":"2026041309331539500_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fimmu.2020.00147","article-title":"Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation","volume":"11","author":"Rovatti","year":"2020","journal-title":"Front Immunol"},{"key":"2026041309331539500_bib29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"2026041309331539500_bib30","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2009-10-201848","article-title":"Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies","volume":"115","author":"O'Keefe","year":"2010","journal-title":"Blood"},{"key":"2026041309331539500_bib31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/leu.2014.314","article-title":"Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation","volume":"29","author":"Crucitti","year":"2015","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"2026041309331539500_bib32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood-2018-99-112142","article-title":"Incidence of HLA loss in a global multicentric cohort of post-transplantation relapses: results from the hlaloss collaborative study","volume":"132","author":"Vago","year":"2018","journal-title":"Blood"},{"key":"2026041309331539500_bib33","doi-asserted-by":"crossref","first-page":"e226114","DOI":"10.1001\/jamanetworkopen.2022.6114","article-title":"Assessment of patient-specific human leukocyte antigen genomic loss at relapse after antithymocyte globulin-based T-cell-replete haploidentical hematopoietic stem cell transplant","volume":"5","author":"Wu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026041309331539500_bib34","doi-asserted-by":"crossref","first-page":"642087","DOI":"10.3389\/fimmu.2021.642087","article-title":"Clinical utility of the detection of the loss of the mismatched HLA in relapsed hematological patients after haploidentical stem cell transplantation with high-dose cyclophosphamide","volume":"12","author":"Mu\u00f1iz","year":"2021","journal-title":"Front Immunol"},{"key":"2026041309331539500_bib35","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat Commun"},{"key":"2026041309331539500_bib36","doi-asserted-by":"crossref","first-page":"9636897221102902","DOI":"10.1177\/09636897221102902","article-title":"Clinical characteristics and outcome analysis for HLA loss patients following partially mismatched related donor transplantation using HLA chimerism for loss of heterozygosity analysis by next-generation sequencing","volume":"31","author":"Wang","year":"2022","journal-title":"Cell Transplant"},{"key":"2026041309331539500_bib37","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041309331539500_bib38","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/blood.2023020731","article-title":"The role of the MDM2\/p53 axis in antitumor immune responses","volume":"143","author":"Brummer","year":"2024","journal-title":"Blood"},{"key":"2026041309331539500_bib39","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2022016082","article-title":"Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","volume":"140","author":"Ho","year":"2022","journal-title":"Blood"},{"key":"2026041309331539500_bib40","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.20080383","article-title":"Transcriptional role of p53 in interferon-mediated antiviral immunity","volume":"205","author":"Mu\u00f1oz-Fontela","year":"2008","journal-title":"J Exp Med"},{"key":"2026041309331539500_bib41","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1158\/2159-8290.CD-20-1741","article-title":"Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity","volume":"11","author":"Zhou","year":"2021","journal-title":"Cancer Discov"},{"key":"2026041309331539500_bib42","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"key":"2026041309331539500_bib43","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","article-title":"Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discov"},{"key":"2026041309331539500_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bcmd.2007.06.029","article-title":"NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation","volume":"40","author":"Ruggeri","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"2026041309331539500_bib45","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"2026041309331539500_bib46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"key":"2026041309331539500_bib47","doi-asserted-by":"crossref","first-page":"e1307491","DOI":"10.1080\/2162402X.2017.1307491","article-title":"NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML","volume":"6","author":"Chretien","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026041309331539500_bib48","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood.2022015522","article-title":"Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse","volume":"140","author":"Gournay","year":"2022","journal-title":"Blood"},{"key":"2026041309331539500_bib49","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2019.01.013","article-title":"Monitoring TIGIT\/DNAM-1 and PVR\/PVRL2 immune checkpoint expression levels in allogeneic stem cell transplantation for acute myeloid leukemia","volume":"25","author":"Hattori","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041309331539500_bib50","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2022015474","article-title":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"2026041309331539500_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kr\u00f6nig","year":"2014","journal-title":"Eur J Haematol"},{"key":"2026041309331539500_bib52","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"2026041309331539500_bib53","doi-asserted-by":"crossref","first-page":"eabb8969","DOI":"10.1126\/scitranslmed.abb8969","article-title":"Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans","volume":"12","author":"Uhl","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026041309331539500_bib54","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/bmt.2010.13","article-title":"Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse","volume":"45","author":"Thiant","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2026041309331539500_bib55","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"2026041309331539500_bib56","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026041309331539500_bib57","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.18632\/oncotarget.1504","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia","volume":"5","author":"Folgiero","year":"2014","journal-title":"Oncotarget"},{"key":"2026041309331539500_bib58","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.12774","article-title":"Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis","volume":"165","author":"Dulphy","year":"2014","journal-title":"Br J Haematol"},{"key":"2026041309331539500_bib59","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-09-375899","article-title":"Deficiency of CD73\/ecto-5\u2032-nucleotidase in mice enhances acute graft-versus-host disease","volume":"119","author":"Tsukamoto","year":"2012","journal-title":"Blood"},{"key":"2026041309331539500_bib60","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041309331539500_bib61","first-page":"2443","article-title":"Up-regulation of iNOS in AML blasts creates an immunosuppressive microenvironment, inhibits T-cell proliferation and transforms T-cells towards a tumor-tolerating phenotype","volume":"130","author":"Jacamo","year":"2017","journal-title":"Blood"},{"key":"2026041309331539500_bib62","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41375-019-0390-3","article-title":"Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically","volume":"33","author":"Mr\u00f3zek","year":"2019","journal-title":"Leukemia"},{"key":"2026041309331539500_bib63","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","article-title":"Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy","volume":"130","author":"Prokocimer","year":"2017","journal-title":"Blood"},{"key":"2026041309331539500_bib64","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1128\/MCB.16.5.2445","article-title":"mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein","volume":"16","author":"Chen","year":"1996","journal-title":"Mol Cell Biol"},{"key":"2026041309331539500_bib65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/10428199509051698","article-title":"Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis","volume":"17","author":"Bueso-Ramos","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"2026041309331539500_bib66","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/ncomms3359","article-title":"p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1","volume":"4","author":"Wang","year":"2013","journal-title":"Nat Commun"},{"key":"2026041309331539500_bib67","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1182\/bloodadvances.2021004908","article-title":"Type 1 interferon to prevent leukemia relapse after allogeneic transplantation","volume":"5","author":"Magenau","year":"2021","journal-title":"Blood Adv"},{"key":"2026041309331539500_bib68","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","article-title":"Functional states of myeloid cells in cancer","volume":"41","author":"van Vlerken-Ysla","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041309331539500_bib69","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026041309331539500_bib70","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1002\/cam4.3360","article-title":"Immunosuppressive role of CD11b+ CD33+ HLA-DR- myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia","volume":"9","author":"Hyun","year":"2020","journal-title":"Cancer Med"},{"key":"2026041309331539500_bib71","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041309331539500_bib72","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1182\/blood-2022-158673","article-title":"Higher proportions of monocytic-myeloid-derived suppressive cells (mMDSC) before allotransplant predict relapse in acute leukemia patients","volume":"140","author":"Peterlin","year":"2022","journal-title":"Blood"},{"key":"2026041309331539500_bib73","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00277-020-03912-y","article-title":"Phenotypic characterization of macrophages in the BMB sample of human acute leukemia","volume":"99","author":"Song","year":"2020","journal-title":"Ann Hematol"},{"key":"2026041309331539500_bib74","doi-asserted-by":"crossref","first-page":"e004794","DOI":"10.1136\/jitc-2022-004794","article-title":"TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis","volume":"10","author":"Brauneck","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026041309331539500_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10456-013-9381-6","article-title":"Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo","volume":"17","author":"Jetten","year":"2014","journal-title":"Angiogenesis"},{"key":"2026041309331539500_bib76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.stem.2017.11.006","article-title":"Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML","volume":"22","author":"Duarte","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"Suppl 1","key":"2026041309331539500_bib77","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2023-190969","article-title":"FLT3-ITD induces immune escape in AML via up-regulating CD47 expression and decreased phagocytic ability of macrophages","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"2026041309331539500_bib78","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2026041309331539500_bib79","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/sj.leu.2404522","article-title":"Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"21","author":"Nadal","year":"2007","journal-title":"Leukemia"},{"key":"2026041309331539500_bib80","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ijc.25791","article-title":"Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia","volume":"129","author":"Shenghui","year":"2011","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"2026041309331539500_bib81","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/S2152-2650(21)01705-5","article-title":"AML-260: influence of chimerism in T-regulatory cells on relapse rate in acute leukemia patients after allo-HSCT","volume":"21","author":"Dubnyak","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041309331539500_bib82","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.2147\/CMAR.S199817","article-title":"Assessment of the presence and anti-tumor potential of tumor-infiltrating lymphocytes in patients with acute myeloid leukemia","volume":"11","author":"Wei","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2026041309331539500_bib83","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.neo.2021.11.003","article-title":"Ex vivo isolation, expansion and bioengineering of CCR7+CD95-\/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow","volume":"23","author":"Cao","year":"2021","journal-title":"Neoplasia"},{"key":"2026041309331539500_bib84","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13287-020-01855-9","article-title":"Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress","volume":"11","author":"Wu","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"2026041309331539500_bib85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s13287-018-1013-z","article-title":"Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival","volume":"9","author":"Corradi","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"2026041309331539500_bib86","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.bbrc.2015.07.002","article-title":"TLR4 plays a crucial role in MSC-induced inhibition of NK cell function","volume":"464","author":"Lu","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"2026041309331539500_bib87","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-13-1656","article-title":"Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment","volume":"74","author":"Ling","year":"2014","journal-title":"Cancer Res"},{"key":"2026041309331539500_bib88","doi-asserted-by":"crossref","first-page":"e15948","DOI":"10.1097\/MD.0000000000015948","article-title":"Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia","volume":"98","author":"Cao","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2026041309331539500_bib89","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3389\/fonc.2020.01672","article-title":"Targeting CXCR4 in AML and ALL","volume":"10","author":"Cancilla","year":"2020","journal-title":"Front Oncol"},{"key":"2026041309331539500_bib90","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1158\/1541-7786.MCR-20-0275","article-title":"Oncogenic KrasG12D activation in the nonhematopoietic bone marrow microenvironment causes myelodysplastic syndrome in mice","volume":"19","author":"Osswald","year":"2021","journal-title":"Mol Cancer Res"},{"key":"2026041309331539500_bib91","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2V617F causes PD-L1 expression mediating immune-escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026041309331539500_bib92","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1158\/0008-5472.CAN-23-3553","article-title":"Oncogenic calreticulin induces immune escape by stimulating TGF-beta expression and regulatory T cell expansion in the bone marrow microenvironment","volume":"84","author":"Schmidt","year":"2024","journal-title":"Cancer Res"},{"key":"2026041309331539500_bib93","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"2026041309331539500_bib94","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"2026041309331539500_bib95","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2026041309331539500_bib96","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2026041309331539500_bib97","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1182\/blood-2022-157606","article-title":"Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine and venetoclax in patients with acute myeloid leukemia (ASPEN-05): results from phase 1a dose escalation part","volume":"140","author":"Garcia-Manero","year":"2022","journal-title":"Blood"},{"key":"2026041309331539500_bib98","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.seminoncol.2010.09.004","article-title":"Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade","volume":"37","author":"Boasberg","year":"2010","journal-title":"Semin Oncol"},{"key":"2026041309331539500_bib99","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/bloodadvances.2022008403","article-title":"Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Godfrey","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0063\/3563466\/bcd-24-0063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/168\/3601202\/bcd-24-0063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/168\/3601202\/bcd-24-0063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:33:35Z","timestamp":1776087215000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/3\/168\/762114\/Immune-Escape-of-Acute-Myeloid-Leukemia-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":99,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,28]]},"published-print":{"date-parts":[[2025,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0063","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}